Evidence map›Paper›PMID 41441885›Full record

ArticleSurgery today2026

Prognostic significance of Albumin-Bilirubin score changes in patients treated with systemic therapy for recurrent hepatocellular carcinoma after liver resection.

Yoh Asahi, Tatsuhiko Kakisaka, Tatsuya Orimo, Shingo Shimada, Akihisa Nagatsu, Takeshi Aiyama, Sunao Fujiyoshi, Yuzuru Sakamoto, Yuki Fujii, Yuichi Yoshida and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yoh AsahiDepartment of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Kita-ku, Kita 14, Nishi 5, Sapporo, 060-8648, Hokkaido, Japan.
Tatsuhiko KakisakaDepartment of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Kita-ku, Kita 14, Nishi 5, Sapporo, 060-8648, Hokkaido, Japan. kakisaka@k2.dion.ne.jp.
Tatsuya OrimoDepartment of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Kita-ku, Kita 14, Nishi 5, Sapporo, 060-8648, Hokkaido, Japan.
Shingo ShimadaDepartment of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Kita-ku, Kita 14, Nishi 5, Sapporo, 060-8648, Hokkaido, Japan.
Akihisa NagatsuDepartment of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Kita-ku, Kita 14, Nishi 5, Sapporo, 060-8648, Hokkaido, Japan.
Takeshi AiyamaDepartment of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Kita-ku, Kita 14, Nishi 5, Sapporo, 060-8648, Hokkaido, Japan.
Sunao FujiyoshiDepartment of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Kita-ku, Kita 14, Nishi 5, Sapporo, 060-8648, Hokkaido, Japan.
Yuzuru SakamotoDepartment of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Kita-ku, Kita 14, Nishi 5, Sapporo, 060-8648, Hokkaido, Japan.
Yuki FujiiDepartment of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Kita-ku, Kita 14, Nishi 5, Sapporo, 060-8648, Hokkaido, Japan.
Yuichi YoshidaDepartment of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Kita-ku, Kita 14, Nishi 5, Sapporo, 060-8648, Hokkaido, Japan.
Shunsuke ShichiDepartment of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Kita-ku, Kita 14, Nishi 5, Sapporo, 060-8648, Hokkaido, Japan.
Ken ImaizumiDepartment of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Kita-ku, Kita 14, Nishi 5, Sapporo, 060-8648, Hokkaido, Japan.
Akinobu TaketomiDepartment of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Kita-ku, Kita 14, Nishi 5, Sapporo, 060-8648, Hokkaido, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo clarify the characteristics of patients who received systemic therapy for recurrent hepatocellular carcinoma after liver resection and evaluate the associated prognostic factors.

methodsWe retrospectively analyzed data from 177 hepatocellular carcinoma patients with recurrence after liver resection; 79 received tyrosine kinase inhibitors or immune checkpoint inhibitors. Prognostic factors were analyzed in the patients who received systemic therapy.

resultsThe median survival time after the initiation of systemic therapy was 23.3 months among the patients who received such therapy. These patients had more advanced disease at recurrence than those who did not receive systemic therapy. In the systemic therapy group, a deterioration of liver function relative to the preoperative status, expressed as the change in the albumin-bilirubin score (≥ 0.469 vs. <0.469), was independently associated with a poorer survival (9.5 vs. 25.2 months, respectively; P = 0.022). Receiving multiple regimens was associated with a longer survival than receiving a single regimen (36.6 vs. 17.7 months, respectively; P = 0.023). Four patients (5.1%) achieved complete remission, two with systemic therapy alone and two after conversion therapy; all achieved a long-term overall survival.

conclusionsA preserved liver function and multiple systemic therapy regimens are favorable prognostic factors. Achieving complete remission results in an improved long-term survival.

Indexed as

BilirubinCarcinoma, HepatocellularHepatectomyImmune Checkpoint InhibitorsLiver NeoplasmsNeoplasm Recurrence, LocalProtein Kinase InhibitorsSerum AlbuminAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesSerum Albumin, Humanalbumin-bilirubin complexBilirubinImmune Checkpoint InhibitorsProtein Kinase InhibitorsSerum AlbuminSerum Albumin, HumanHepatocellular carcinomaImmune checkpoint inhibitorLiver resectionRecurrenceTyrosine kinase inhibitor

Identifiers

PMID41441885

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.